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Major functions of iron, as an essential element for living organisms, are oxygen
transport and its role in oxidative-reductive reactions that utilize its alternative ferrous-
-ferric states. Total body iron has to be strictly controlled because excess iron can be hig-
hly toxic, leading, through generation of reactive oxygen species (ROS), to iron overloa-
ding disorders (1, 2). Iron chelating therapy has long been the standard care for patients
suffering from Thalassemias (anemias caused by mutation of globin genes) and other ane-
mias, caused e.g. by renal dysfunction (lack of erythropoietin (EPO) production), and for
patients receiving transfusion iron supplementation. Iron chelators are used to treat dia-
lyzed patients; in kidney transplantation, cardiac diseases, malaria, iron poisoning, and
can inhibit tumor cell growth. They are also used to stimulate EPO production (3–5).
Various structures of iron chelates have been investigated but the best known and
in use for more than 40 years is desferrioxamine (DFO), despite its poor membrane per-
meability, short shelf life, difficulties in application and expensiveness. DFO is a natural
hydroxamic acid (HA) of the microorganism Streptomyces sp. and belongs to sideropho-
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res, compounds that are able to solubilize environmental iron hydroxides and, by form-
ing a complex, transport iron into the cell (6, 7).
Some pharmacological activities of HA structures could be explained by iron chelat-
ing, e.g., antibacterial activity due to inhibition of peptide deformylase as well as anti-in-
flammatory activity owing to inhibition of lypooxygenase (5-LO) (8–10).
In this work, we have studied the influence of N-phthaloyl-glycine-hydroxamic acid
(Phth-Gly-HA) on iron levels in rat serum, with the goal of finding a potentially successful
new chelator for iron overload diseases.
EXPERIMENTAL
Chemistry
N-phthaloyl-glycine-hydroxamic acid (Phth-Gly-HA) was synthesized in three steps
according to a modified procedure (11). Glycine with phthalanhydride gave N-phtha-
loyl-glycine, which was by thionyl chloride converted to N-phthaloyl-glycine-chloride
and finally, in the reaction with hydroxylamine hydrochloride N-phthaloyl-glycine-hy-
droxamic acid C6H4(CO)2NCH2CONHOH was prepared. Modifications were made in
the third step of the synthesis. Higher excess of hydroxylamine, liberated from hydroc-
hloride, towards relevant acyl-chloride was used, and the reaction was carried out by
adding small portions of reactants alternatively, instead of all at the same time, to avoid
possible decomposition of the product. In the course of synthesis, as well as separation
by column chromatography and purification by crystallization, hydroxamic acid was
detected due to intensive colour with FeCl3 solution.
Animals, laboratory equipment and methods
Investigations of the chelating ability of the test compound under in vivo conditions
were performed on Wistar rats of both genders (males weighing about 350 g and fema-
les 200–250 g). Care and treatment of experimental animals followed recommended gui-
delines (Approval by the Institutional Ethical Committee).
Three groups of male rats were formed. The first group (n = 10) served as control,
the second (n = 4) was treated with the studied substance only once and the third group
(n = 4) was treated for seven days, once a day, with the test substance.
Two groups of female rats were formed, the first (n = 3) as control and the second (n
= 3) for the seven-day treatment.
The substance examined, Phth-Gly-HA, was prepared for application as a water so-
lution in a concentration of 0.1 mg mL–1. The same volume (3.5 mL per animal) of the test
solution was injected intraperitoneally into both genders. The control group received 3.5
mL of physiological saline. The applied dose of Phth-Gly-HA (0.35 mg) was 1 mg kg–1
body mass of male rats and 1.5 mg kg–1 body mass of female rats.
Blood samples were taken from the tested animals after one day from male rats and
after seven days from both genders. The level of serum iron was measured. Samples (up
to 2 mL) from treated as well as from control animals were taken from vena jugularis
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with a short surgical procedure under short anesthesia with diethyl ether. The blood
was collected directly into the test tube with resin for serum separation. The blood sam-
ples were left about 30 min at room temperature (21 °C) and centrifuged 10 min at 2000
rpm. Serum was separated from the sediment and analyzed by the TPTZ 2,4,6-tris(2-py-
ridyl)-s-triazine method (12). Iron determination was performed by commercially avail-
able tests on an automated analyzer Olympus 600 (WB Saunders Company).
RESULTS AND DISCUSSION
The values of serum iron in rats before and after application of active substance are
shown in Tables I and II. Using intraperitoneal application (1 mg kg–1) of Phth-Gly-HA
for seven days, once a day, the levels of serum iron decreased from average 37.8 mmol
L–1 to 29.8 mmol L–1 for male rats (Table I), i.e., they decreased by 21%. After treatment of
female rats (1.5 mg kg–1) for seven days, once a day, the serum iron decreased from 59.3
mmol L–1 to 38.3 mmol L–1 (Table II), i.e., dropped by 35%. Interestingly, treatment of ma-
le rats for only one day led to quite a large decrease of iron (68% of the control) (Table I).
The assumption that some regulatory and compensatory mechanisms are involved after
a few days, which could inhibit further decrease of serum iron, could be taken into con-
sideration. A feedback regulation of iron absorption into the gastro-intestinal tract, which
is regulated by a mucosal receptor blocking further iron absorption after it is saturated,
is possible (1).
The obtained results show that Phth-Gly-HA possesses serum iron chelation ability,
mostly from transferrin iron. The main goal in designing new chelators is actually to
mobilize stored iron, ferritin, as well. Still, the best chelator for medicinal purposes,
DFO, can extract stored iron with difficulty. It is possible that Phth-Gly-HA could remo-
ve ferritin iron owing to the recent knowledge about the relationship between the corre-
sponding structures and properties of numerous examined chelators (6).
DFO, as a hexadentate ligand with three hydroxamic groups, forms a 1:1 stable
complex with the ferri ion, preventing ROS formation. Hexadentate chelators with bul-
ky mass (600–900 Da) possess lower bioavailability. However, bidentate ligands such as
Phth-Gly-HA and some other HAs with one hydroxamic moiety, or hydroxypyridones
like deferiprone, form iron complexes at a ratio 3:1, which are less stable, less inert and
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10 Control 37.8  2.4 
4 1 25.8  0.4 68
4 7 29.8  2.4 79
a 1 mg kg1 body mass for one day and seven days
thus more soluble, which could help chelation of storage iron. For this reason, as well as
owing to smaller size (100–250 Da), bidentate ligands have higher bioavailability that
additionally grows with lipophilicity, based on hydrophobic interactions with metallo-
proteins. Further advantage of the small-size chelators is that no bidentate interaction is
possible between ligand and porphyrin-bound iron. Iron redistribution from such com-
plexes is still possible. Acetohydroxamic acid (75 Da), benzohydroxamic acids (137 Da)
and deferiprone (139 Da) showed the ability of passing narrow ferritin channels leading
to stored Fe(III) ions, which were chelated directly. However, some chelators have to re-
duce ferric ions to a more mobile ferro form before complexation and then oxidation to a
stable ferri complex follows. The efficacy of chelation depends on a number of factors.
Due to negatively charged ferritin channels, medium pH and chelator charge are impor-
tant. The presence of urea, capable of broadening ferritin channels, strongly increases
the effectiveness of chelation. There is still inadequate understanding of all the mecha-
nisms of chelator entry to ferritin, mobilization of iron and exit of the formed complexes
(13–16).
To avoid undesirable effects of particular commonly used chelators, recently combi-
ned drugs, e.g., the hexadentate DFO and the bidentate deferiprone, have been used.
Search for better human iron chelators still remains a challenge (6, 17).
CONCLUSIONS
Phth-Gly-HA decreases the level of serum iron in rats by complexation of transfer-
rin iron and probably also part of ferritin iron. This assumption is based on monohydro-
xamic acid structure of the chelator, being a bidentate ligand of considerable lipophili-
city due to its aromatic ring rather than to bulky mass (220 Da). According to these
properties, Phth-Gly-HA should possess high bioavailability, which could be of thera-
peutic use.
Our hypothesis needs to be confirmed by further experiments. It will be interesting to
know the portion of ferritin iron, examine the influence of this chelator on EPO produc-
tion, determine the chelation capacity in dependence on pH values (differences beween
physiological pH and pH under some pathological conditions), or the chelation efficacy
with a catalyst such as urea. Its possible application in humans should be examined.
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3 Control 59.3  3.7 
3 7 38.3  1.8 65
a 1.5 mg kg1 body mass for seven days
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S A @ E T A K
N-ftaloil-glicin-hidroksamska kiselina kao kelator `eljeza u serumu {takora
JULIJA MATIJEVI]-SOSA, ITA SAMAR@IJA, LORENA HONOVI] i BLA@ENKA JURI[I]
U cilju pronala`enja novog efikasnog kelatora koji bi mogao poslu`iti u lije~enju bo-
lesti izazvanih vi{kom `eljeza, u ovom je radu ispitano djelovanje N-ftaloil-glicin-hid-
roksamske kiseline (Phth-Gly-HA) in vivo. Istra`ivan je utjecaj kelatora na razinu `eljeza
u serumu {takora nakon intraperitonealne primjene vodene otopine Phth-Gly-HA (0,1
mg mL–1) jednom dnevno tijekom 7 dana. Kontrolne su `ivotinje primale fiziolo{ku oto-
pinu. Kod mu`jaka injektiranje test supstancije (1 mg kg–1) uzrokovalo je pad serum-
skog `eljeza za 21%. Kod `enki je nakon tretmana (1,5 mg kg–1) izmjereno sni`enje ra-
zine `eljeza za 35%. Rezultati pokazuju da ispitivana supstanca ima sposobnost kom-
pleksiranja serumskog `eljeza, prete`no transferinskog, ali da postoji mogu}nost mobili-
zacije `eljeza i iz feritinskih zaliha.
Klju~ne rije~i: N-ftaloil-glicin-hidroksamska kiselina, kelatori `eljeza, bolesti uzrokovane vi{kom
`eljeza
Farmaceutsko-biokemijski fakultet Sveu~ili{ta u Zagrebu, Zagreb
Op}a bolnica Pula
Agencija za lijekove i medicinske proizvode, Zagreb
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